A single entity amphetamine product combining the neutral sulfate salts of dextroamphetamine and amphetamine, with the dextro isomer of amphetamine saccharate and d, l-amphetamine aspartate.
Attention Deficit Disorder with Hyperactivity: Adderall is indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted.
Media Articles Related to Amphetamine
Antiretroviral therapy benefits HIV-infected stimulant users, UCSF study shows
Source: HIV / AIDS News From Medical News Today [2014.10.14]
New clinical research from UC San Francisco shows that 341 HIV-infected men who reported using stimulants such as methamphetamine or cocaine derived life-saving benefits from being on...
Published Studies Related to Amphetamine
A retrospective analysis of two randomized trials of bupropion for
methamphetamine dependence: suggested guidelines for treatment
BACKGROUND: Two clinical trials have shown efficacy for bupropion in treating
methamphetamine (MA) dependence among those with moderate baseline MA use. However, treatment response is highly variable and it is unclear what duration of
treatment is necessary to determine if maintaining the treatment course is
indicated or if discontinuation or augmentation is appropriate.
Dexamphetamine improves upper extremity outcome during rehabilitation after stroke: a pilot randomized controlled trial. [2011.10]
BACKGROUND: For early inpatient stroke rehabilitation, the effectiveness of amphetamine combined with physiotherapy varies across studies. OBJECTIVE: To investigate whether the recovery of activities of daily living (ADL, primary outcome) and motor function (secondary outcome) can be improved by dexamphetamine added to physiotherapy... CONCLUSION: In this small trial that was based on prior positive trials, significant gains in ADL and arm function suggest that the dose and timing of dexamphetamine can augment physiotherapy. Effect size calculation suggests inclusion of at least 25 patients per group in future studies.
Medication adherence and symptom reduction in adults treated with mixed amphetamine salts in a randomized crossover study. [2011.09]
OBJECTIVES: The study objectives were to 1) evaluate medication adherence for adults with attention-deficit/hyperactivity disorder (ADHD) treated with 3 times daily (TID) mixed amphetamine salts immediate release (MAS IR) versus once-daily (qAM) MAS extended release (MAS XR) in a randomized, crossover study; and 2) to examine the associations between adherence and efficacy for MAS IR and MAS XR... CONCLUSION: Adults with ADHD adhered equally well with MAS IR as with MAS XR when assessed by pill count and self-report, but not by the MEMS((R)) measures. Both treatments significantly reduced ADHD symptoms, and efficacy was not significantly different between groups. Adherence was not associated with treatment outcome.
The influence of depression on treatment for methamphetamine use. [2011.08.01]
OBJECTIVE: To determine whether the presence of comorbid depression influences response to psychological treatment for methamphetamine use... CONCLUSIONS: Over the short term, comorbid depression did not negatively affect response to treatment, with some evidence of a dose-response treatment effect for reduction in depression. This was not maintained at 6 months, indicating that methamphetamine-focused treatment may not enable people with comorbid depression to make sustained improvement at the level of their counterparts without depression. TRIAL REGISTRATION NUMBER: ACTRN12611000355976.
Quality of life among treatment seeking methamphetamine-dependent individuals. [2011.07]
As the number of men and women entering treatment for substance use disorders continues to increase across the country, it becomes vitally important to understand their quality of life (QOL) or perceived health status, in order to inform treatment efforts for improving such outcomes.
Clinical Trials Related to Amphetamine
Dose Response of Mirtazapine to Methamphetamine Induced Interest, Mood Elevation and Reward [Recruiting]
The primary purpose of this study is to determine if Mirtazapine will produce a decrease in
interest in the drug, a decrease in mood elevation, and/or a decrease in reward when given
before methamphetamine compared to placebo.
Participants will be screened with a psychiatric interview, medical history and physical,
laboratory tests, drug of abuse screen and, if female, a urine pregnancy test. They will be
provided written informed consent. They will be studied in a within-subjects examination of
the subjective mood responses of mirtazapine and methamphetamine. Interactions between
methamphetamine and mirtazapine will be assessed by pharmacokinetic studies. Each
participant will be introduced to rating scales and cognitive tasks described below.
Participants will remain in the research unit for 5 hours on each day that they receive
study medication or placebo. They will spend five days in total on the research unit, one
day separated by at least one day; then in two day blocks separated by at least one day from
another two day block. A venous catheter will be placed for blood draws. Blood pressures and
heart rates will be recorded and assessed. Participants will be randomized and double
blinded to receive either placebo or mirtazapine orally two hours prior to the
administration of randomized and double blinded methamphetamine or placebo in order to have
the peak effects of the drugs overlap. VAS-mood, ARCI, GRS, POMS and POMS-E, neurocognitive
tasks Trails A and B and Symbol digits modalities test will be administered prior to the
mirtazapine or placebo dose, and repeated after the administration of methamphetamine or
placebo. After the administration of methamphetamine or placebo, vital signs will be
assessed every 15 minutes and the measures will be repeated until 120 minutes have passed
from the initial dose of methamphetamine or placebo. Blood will be drawn at one, three and
four hour marks for pharmacokinetic testing. This will be repeated on each testing day.
Studying Amphetamine Withdrawal in Humans [Recruiting]
Methamphetamine use is very common in the US and is associated with serious medical and
psychiatric problems. There has also been a significant increase in the number of patients
entering treatment for methamphetamine dependence, however, no pharmacologic treatment has
been identified as effective in treating methamphetamine addiction. Given that withdrawal
from methamphetamine is thought to contribute to relapse to methamphetamine use during early
treatment, it is important to examine potential pharmacologic agents for alleviating
withdrawal. Thus, this study is designed to study methamphetamine withdrawal in humans. To
this end, 30 methamphetamine dependent participants (ages 18-65 years) will be entered into
a 4-week residential study. Urine samples will be obtained at baseline to ensure recent
methamphetamine use. Intake assessments will include cognitive testing, standardized
assessment of depression and anxiety, profile of mood states, methamphetamine selective
severity assessment, methamphetamine withdrawal assessment, sleep quality and quantity, a
pre-attentional measure and attentional measure. Upon admission to the residential
facility, all study participants will be started on (20-30mg) long acting
amphetamine/d-amphetamine and stabilized over the first 5 days. After stabilization
participants will be randomized based on sex, amphetamine withdrawal questionnaire score,
and methamphetamine selective severity assessment score to either continued treatment with
amphetamine/d-amphetamine or placebo for 2 weeks. All subjects will then be placed on
placebo for the last 7 days. The investigators hypothesis is that stopping amphetamine
administration in methamphetamine dependent individuals will negatively impact mood, sleep
and cognitive function in a time-limited fashion that may differ depending upon the measure
and that attentional, but not pre-attentional, measures will be adversely affected in those
receiving placebo compared to those maintained on amphetamine.
A Dose Ranging Study of Modafinil for Methamphetamine Dependence [Recruiting]
Patients treated for methamphetamine dependence have high rates of relapse, and no
pharmacotherapy has yet been demonstrated to be efficacious. Modafinil (d,
l-2-[(diphenylmethyl)sulfinyl]acetamide) is a novel wake- and vigilance-promoting agent that
is chemically and pharmacologically dissimilar to CNS stimulants. It is well tolerated and
has low abuse liability compared to CNS stimulants. Modafinil is FDA approved for a variety
of sleep disorders, may relieve methamphetamine withdrawal symptoms, improves cognitive
function, has been shown to reduce cocaine use in dependent users, and is safe when
coadministered with intravenous methamphetamine. We will conduct a randomized dose ranging
clinical trial of modafinil to establish its safety and efficacy as a pharmacotherapy for
Effects of Contingency Management for Methamphetamine Abstinence on Post-Exposure Prophylaxis for HIV in Men Who Have Sex With Men (MSM) [Recruiting]
This study seeks to decrease methamphetamine use and concomitant high-risk sexual behaviors
among methamphetamine-using men who have sex with men (MSM) by combining a biomedical
intervention with a behavioral intervention. The behavioral intervention will consist of an
8-week course of contingency management (CM) through which participants will be reinforced
for testing negative for methamphetamine metabolites during periodic urine analyses. The
biomedical intervention involves a 28-day course of an antiretroviral drug (Truvada) to be
administered after an unanticipated HIV risk exposure (i. e., engaging in either receptive or
insertive anal sex without a condom with someone who is HIV-positive or of unknown status).
In combining these two interventions, this study seeks to evaluate the combined
intervention's effects on sexual risk behaviors and methamphetamine use.
Behavioral Activation and HIV Risk Reduction for Men Who Have Sex With Men With Crystal Meth Abuse [Recruiting]
The purpose of this study is to research a new behavioral treatment to reduce sexual
risk-taking in men who have sex with men (MSM) who abuse crystal methamphetamine (crystal
meth), and are at risk for HIV acquisition. This study proposes using a treatment based on
our original pilot study that incorporates risk reduction and behavioral activation therapy.
In order to help learn what types of treatment programs best help individuals who abuse
crystal meth and engage in sexual risk-taking, we will compare our treatment to a control
group. The treatment group will receive therapy incorporating behavioral risk reduction
counseling with behavioral activation therapy to treat depression, helping individuals
reengage in their life. The control group will receive the risk reduction counseling
without the behavioral activation therapy. The current study hopes to explore the efficacy
of this previous developed treatment in a two-arm pilot randomized controlled trial.
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 1 ratings/reviews, Amphetamine has an overall score of 9. The effectiveness score is 8 and the side effect score is 8. The scores are on ten point scale: 10 - best, 1 - worst.
Amphetamine review by 52 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Considerably Effective|
|Side effects:|| || Mild Side Effects|
|Condition / reason:|| || ADD|
|Dosage & duration:|| || 30mg taken once daily for the period of 1 year|
|Other conditions:|| || none|
|Other drugs taken:|| || none|
|Benefits:|| || Elimated restless feeling and able to sleep at night. The main thing is that I do not go off the deep end when something goes wrong or that I do not control. I also had the side / added benefit of dropping fifteen pounds within the first two monhts of starting medication which also naturally makes you feel better as well.|
|Side effects:|| || Taken on an empty stomach, it makes you a little jittery|
|Comments:|| || My doctor recommended this course of treatment after several visits and it has worked very well for me.|
Page last updated: 2014-10-14